Allergy Therapeutics plc has disclosed a Form 8.5 (EPT/RI) from Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The form provides key information regarding dealings in Allergy Therapeutics' securities. The dealings were undertaken on September 28, 2023. The form includes details of purchases and sales of the company's 0.1p ordinary shares, with a total of 1,637,044 shares purchased at a highest price per unit of 0.01585 and a lowest price per unit of 0.0148. Additionally, 1,518,159 shares were sold at a highest price per unit of 0.0169 and a lowest price per unit of 0.01598.

The form does not disclose any cash-settled derivative transactions or stock-settled derivative transactions, including options. It also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing. Furthermore, there are no agreements, arrangements, or understandings relating to options or derivatives.

The contact person for this disclosure is Freddie Wooding, and the date of disclosure is September 29, 2023. The form emphasizes that public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service, and the Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.